Is it Time to Dump CASI Pharmaceuticals Inc (CASI) Stock After it Is Up 15.22% in a Week?

The market has been high on CASI Pharmaceuticals Inc (CASI) stock recently. CASI gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CASI Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CASI!

See Full CASI Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CASI Stock Today?

CASI Pharmaceuticals Inc (CASI) stock is trading at $5.30 as of 10:06 AM on Monday, Nov 27, a decline of -$0.55, or -9.4% from the previous closing price of $5.85. The stock has traded between $5.06 and $5.31 so far today. Volume today is low. So far 34,677 shares have traded compared to average volume of 46,317 shares.

More About CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. Click Here to get the full Stock Report for CASI Pharmaceuticals Inc stock.